Actithera significantly strengthens leadership team and Board as Company advances towards clinical development
- Steven Kelly appointed Chief Executive Officer to lead Actithera through clinical development and continued pipeline expansion
- Briggs Morrison appointed Chair of the Board, bringing extensive biotech leadership and oncology drug development expertise
- John Crowley appointed Independent Director, adding proven strategic, financial and capital markets leadership
Oslo, Norway and Cambridge, Massachusetts — 10 September 2026 — Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), today announced the appointment of Steven Kelly as Chief Executive Officer and a member of its Board of Directors, alongside the appointment of Briggs Morrison as Chair of the Board and John Crowley as an independent director. The appointments strengthen Actithera’s leadership team as the company advances into clinical development and enters its next phase of growth.
